Bridgeway Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Bridgeway Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$290K	Hold	59,900	–	–	0.01%	981
2026 Q1	$205K	Hold	59,900	–	–	﹤0.01%	1033
2025 Q4	$68.3K	Hold	59,900	–	–	﹤0.01%	1164
2025 Q3	$76.1K	Hold	59,900	–	–	﹤0.01%	1134
2025 Q2	$63.5K	Hold	59,900	–	–	﹤0.01%	1119
2025 Q1	$81.5K	Sell	59,900 -102,300	-63%	-$129K	﹤0.01%	1073
2024 Q4	$224K	Sell	162,200 -34,800	-18%	-$42.2K	0.01%	980
2024 Q3	$211K	Buy	197,000 +92,708	+89%	+$161K	﹤0.01%	1054
2024 Q2	$224K	Buy	104,292 +78,000	+297%	+$186K	0.01%	1034
2024 Q1	$85.4K	Sell	26,292 -10,700	-29%	-$116K	﹤0.01%	1223
2023 Q4	$758K	Sell	36,992 -10,508	-22%	-$176K	0.02%	830
2023 Q3	$764K	Buy	47,500 +20,000	+73%	+$226K	0.02%	778
2023 Q2	$234K	Sell	27,500 -25,000	-48%	-$180K	0.01%	1098
2023 Q1	$518K	Buy	+52,500	New	+$584K	0.01%	878

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Bridgeway Capital Management's ANTX Position: Q2 2026 in Review

Bridgeway Capital Management held its AN2 Therapeutics (ANTX) position steady in Q2 2026 at 59,900 shares worth $290K. The position accounts for 0.01% of the portfolio, ranked #981.

Bridgeway Capital Management first reported a position in ANTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $764K in Q3 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Bridgeway Capital Management held 59,900 shares of AN2 Therapeutics worth $290K as of Q2 2026.
Bridgeway Capital Management left its AN2 Therapeutics share count unchanged in Q2 2026.
AN2 Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #981 holding.
Bridgeway Capital Management first reported a position in AN2 Therapeutics in Q1 2023 and has held it in 14 quarters since.
Bridgeway Capital Management's AN2 Therapeutics position peaked at $764K in Q3 2023.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.